Inactivation or attenuation; producing viral sub-units (C12N7/04)

Polycationic triviron compound and method for production thereof

Method for synthesis of a 1,5-bis-(4-tetradecyl-1,4-diazoniabicyclo[2.2.2]octan-1-yl)pentane tetrabromide (C47H100Br4N4) derivative includes dissolving 1-tetradecyl-4-aza-1-azoniabicyclo[2.2.2]octane bromide in methanol while heating to temperature of 55°C, while stirring, adding two portions 1,5-dibromomethane to the obtained solution until a reaction mixture is obtained, which is then stirred and cooled to temperature of 18-22°C, after which 20 ml acetonitrile is added to the obtained mixture, followed by separation of the precipitate from the mother solution, wherein the precipitate is filtered out and dried in a vacuum and the obtained mother solution is evaporated to obtain a viscous syrup-like residue to which 40 ml acetonitrile is added and stirred while boiling with a reflux condenser to obtain a suspension which is then cooled to temperature of 18-22°C and the precipitate formed is filtered out, dried in a vacuum and mixed with the previously obtained precipitate to obtain the end product.

Attenuated recombinant parvovirus applicable for dog protection against parvovirus infection

Group of inventions refers to viral vaccines for the dog protection against parvovirus infection, preparing and using them. More specifically, the invention refers to an attenuated recombinant parvovirus containing a DNA sequence of type 2 first attenuated parvovirus with the DNA coding a capsid protein of the first parvovirus is substituted by a capsid protein of type 2c parvovirus. The vaccine on the basis of the above virus is able to induce higher titres of the protective antibodies against a risk of type 2c parvovirus infection, preserving at the same time a good immunity against type 2 parvovirus. The strains of the recombinant virus also have been found to remain attenuated.

Cattle diarrhea virus with modified e^rns protein

Claimed invention relates to the field of biotechnology and virology. Described is a chimeric pestivirus, where the said chimeric pestivirus includes the cattle diarrhea virus, which does not express its homologous Erns protein. The said chimeric pestivirus expresses a heterologous Erns protein, originating from the other pestivirus, or a natural, synthetic or genetic version of the said heterologous Erns protein. Also described are methods and sets for treatment or prevention of propagation of the infection, caused by the cattle diarrhea virus, as well as methods for a differentiation between the vaccinated animals and the animals, infected with the virus of a wild type.

Recombinant classical swine fever virus (csfv), which contains modified protein e2, and creation methods of above described recombinant csfv

Invention proposes recombinant classical swine fever virus (1111) that contains deletion of at least one amino-acid in TAVSPTTLR domain of protein E2, which corresponds to positions 829-837 of parent polyprotein CSFV, as well as the corresponding vaccine, kDNA molecule, a protection method of an animal against CSFV and a differentiation method of CSFV-infected animals.

Nanocomposite with active ligand, method of its preparation and method of address inactivation of flu virus inside cell

Nanocomposites made of nanoparticles of titanium dioxide in amorphous or crystalline (anatase, brookite) form, immobilised polylysine derivatives of oligonucleotides (PL-oligo) and photoactivated arylazide groups introduced in amino groups of polylysine. All components of the nanocomposite perform a certain function: TiO2-nanoparticles support transfection of cells; polylysine helps to immobilise oligonucleotide onto the surface of nanoparticles and adds functional groups (NH2), which make it possible to add additional reaction-capable groups; oligonucleotides of certain sequence forward the composite towards the target sections of the virus RNA; the photoactivated perfluoroarylazide group after irradiation with light may damage nucleic acids.

Method for producing preparation containing viral antigens and using preparation

Invention refers to molecular biology, genetic engineering and virology. What is presented is a method for producing a preparation containing the viral antigens, involving a) cell inoculation with an infectious in the fluid, b) reproduction of the above virus in the above cells, c) collection of the above reproduced virus, d) inactivation of the above collected virus, and e) treatment of the above inactivated virus with a detergent to produce the preparation containing the viral antigens.

Method to determine virulent and pathogenic forms of flu viruses

Method to determine virulent and pathogenic forms of flue viruses is based on collection of an initial sample of a tissue/physiological fluid from patients who are possibly sick with flu, extraction and treatment of RNA preparations from the initial sample, synthesis of cDNA on the RNA matrix, analysis of a nucleotide sequence of the produced cDNA with the purpose to identify the mutation status of specific positions of flu virus segments, and calculation of two scoring-factors, by the value of which they decide on extent of virulence and pathogenicity of a flu virus.

Method to produce flu virus

Method to produce a flu virus is proposed, according to which hens are injected with a vaccine against flu, eggs are collected from vaccinated hens, the process of embryogenesis is initiated, eggs with a developing embryo are infected, introducing a flu virus into an allantoic cavity, infected eggs with developing embryos are incubated under temperature and moisture, which provide for virus replication, and the allantoic liquid is collected, which contains a virus. Also application of the flu virus and eggs produced by this method is proposed.

Methods of packaging of oligonucleotides into virus-like particles of rna-containing bacteriophages

Method of preparation of composition comprising (i) virus-like particles is described, and the said virus-like particles are virus-like particles of RNA-containing bacteriophage, and (ii) an oligonucleotide, and the said oligonucleotide is packaged in the said virus-like particles. Also a method of production of nucleotide composition comprising oligonucleotides used in the above mentioned methods is described. Also the nucleotide composition produced with the method of this invention and their application is described. The said composition preferably has a purity of at least 98%, most preferably at least 99%. The invention can be used in medicine.

Influenza a virus propagation inhibitor on basis of complex of titanium dioxide nanoparticles and oligonucleotide

What is presented is an influenza A virus propagation inhibitor; the inhibitor represents a complex of titanium dioxide nanoparticles and virus-specific deoxyribozyme. Deoxyribozyme is presented by an oligonucleotide of the following nucleotide sequence - 5'-GAAATAAGAGGCTAGCTACAACGACCTTCATTA.

Methods and compositions for expressing negative-sense viral rna in canine cells

Invention is an isolated nucleic acid comprising a canine RNA polymerase I regulatory sequence and containing (i) at least 250 or at least 350 or at least 450 adjoining nucleotides or an entire nucleotide sequence, which is in form of SEQ ID NO:26, (ii) a nucleotide which is at least 80% identical to said nucleotide sequence (i) or includes a complementary or reverse complementary (i) or (ii) sequence. The nucleotide sequence (i) or (ii) is operably linked to cDNA which encodes influenza virus vRNA, and when produced in MDCK cells, is capable of directing expression of said influenza virus vRNA. The present invention also describes expression vectors and cells containing such nucleic acids, as well as methods of using such nucleic acids to obtain influenza viruses, including infectious influenza viruses.

New type of carrier particles (platforms) for production of active complexes

FIELD: biology, medicine, nanotechnology. SUBSTANCE: group of inventions is referred to the area of biology, medicine, nanotechnology and involves processing of new platform carriers for formation of complexes with biologically active compounds. The proposed platform carriers are of spherical shape and are made by the way of thermal reconfiguration of structure of tobacco mosaic virus (TMV) or another tobamovirus or another plant virus with spiral structure or their fragments. The platform carriers are also produced by the way of thermal reconfiguration of coat protein of TMV group virus (tobamoviruses) or another phytovirus with spiral structure or their fragments. There were also proposed the compositions containing the platform-carrier of said spherical carrier connected with the alien protein or another biologically active compound. The advantages of new platform carriers include the simplicity and quickness of production, possibility to get spherical particles of regulated sizes, long term storage, absence of aggregation and preservation of spherical shape during its storage, centrifugation and resedimentation, the convenience of spherical particles shape for formation of complexes with target compound. EFFECT: important feature of a new carrier platform is the capability to adsorb on the surface and to form compositions with different structurally and functionally alien proteins/antigens. 3 cl, 6 ex, 10 dwg

Interleukin-1 conjugates and their application

What is described is a composition containing an ordered antigen pattern where antigen represents IL-1, mutein IL-1 or fragment IL-1. There is also offered a based vaccine. The compositions offered in the invention can be applied for producing vaccines for inflammatory diseases and chronic autoimmune diseases, transmittable diseases and cardiovascular diseases.

Conditionally defective particle of influenza virus and methods of producing thereof (versions)

Disclosed is a conditionally defective particle of influenza virus with the absence of a nucleic acid segment of influenza virus selected from a group of segments, mainly coding acid polymerase (PA), basic polymerase 1 (PB1) and basic polymerase 2 (PB2). The conditionally defective particle of influenza virus is used for induction of influenza virus defence. Also, a method of producing such particles, a pharmaceutical composition containing such particles, its application and a method of induction of influenza virus defence are described.

Deoxyribozyme for inhibiting influenza a virus reproduction

Invention is intended for inhibiting reproduction of influenza A viruses in infected eukaryotic cells by means of virus-specific catalytically active oligodeoxyribonucleotide (deoxyribozyme). Method is realised by obtaining deoxyribozyme, consisting of nucleotide sequence: 5'-GAAATAAGAGGCTAGCTACAACGACCTTCATTA, intended for inhibiting reproduction of influenza A viruses.

N-substituted 1,4-diazabicyclo-[2,2,2]-octane derivatives exhibiting rna-antiviral activity

Invention refers to new compounds which are N-substituted 1,4-diazabicyclo[2.2.2.]octane derivatives. The offered compounds exhibit antiviral activity and can find application in medicine as active components for the development of dosage forms used for treating viral diseases.

Mutant virus of bull diarrhea

Invention relates to field of veterinary and deals with mutant virus of bull diarrhea. Essence of invention includes virus of bull diarrhea, containing at least one amino acid mutation of helicase domaine, where mutation in domain NS3 results in loss of recognition by monoclonal antibody, generated against wild type of NS3, but were virus RNA replication and generation of infectious virus are preserved. Second version includes virus of bull diarrhea containing at least one mutation in helicase domain, where mutation is in helicase domain in IGR loop and/or in KHR loop and/or in SES loop.

Modified recombinant vaccinating viruses and other microorganisms and their application

Recombinant virus of cowpox contains virus of cowpox, which includes modified gene of thymidine-kinase (TK), modified gene HA and modified gene F3 or broken locus F3. At the same time each of TK, HA and F3 gene or locus of cowpox virus is inactivated, and F3 gene or locus is located in fragment HindIII-F of cowpox virus between open reading frames F14L and F15L.

Method of blocking chronic integration infection caused by human immunodeficiency virus

Invention can be applied for blocking of chronic integration diseases caused by human immunodeficiency virus (HIV), bovine leucosis virus (BLV), bovine immunodeficiency virus (BIV), mouse leucosis virus (MuLV), equine infection anemia virus (EIA) and hepatitis B virus. Effect is achieved by application of live cells of Mycoplasma arginini microbe non-pathogenic to humans, used for superinfection of T lymphocyte infected with HIV.

Method for preparing genetically modified influenza virus and virus proteins and application thereof

Method provides target modification of virulent properties of influenza virus by genetic modification of caspase and granzyme viral proteolysis sites. There is also described application of such genetically modified influenza virus as vaccines and therapeutic agents, translation and expression vectors of biologically active genetic elements, polypeptides and fragments thereof in an organism-recipient for metabolism targeting in bodies and tissues and as agents for selective elimination of damaged and tumour cells in an organism. The invention can be used in medicine.

Method for virus controlling using substance based on 2,8-dithioxo-1h-pyrano[2,3-d;6,5-d']dipyrimidine and 10-aza- analogs thereof (variants)

Invention relates to method for virus controlling using substance based on 2,8-dithioxo-1H-pyrano[2,3-d;6,5-d']dipyrimidine and 10-aza- analogs thereof. Claimed method includes sharing said substances together with integrase inhibitor, reverse transcriptase inhibitor, ore protease inhibitor in various ratio (variants).